Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Find effective ways to earn money freelancing online and enhance your income. Explore the best platforms and strategies.
12,564 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
World Liberty Financial, linked to the Trump family, launches a defamation lawsuit against a billionaire after a prev...
A veteran portfolio manager recounts selling a 19-bagger too early and explains how that misstep reshaped his long-te...
Investors often ask where XRP will be in three years. This article examines bear, base, and bull scenarios, plus prac...
When mortgage markets swung on interest-rate headlines, one fund pressed deeper into PennyMac. This article explains ...
When markets hit new highs, Berkshire Hathaway's leaders offer a different playbook. Learn how Warren Buffett's Greg ...
Income investors are eyeing a familiar Dividend King delivering a near-3% yield. This article breaks down what that s...
The AI era hinges on memory and data storage, not just fast processors. This article explains why a memory-focused AI...
May often stirs market chatter about seasonal weakness, yet patient investors can find lasting value. Here are two gr...
Telos (TLS) 2026 earnings outlook is shaping up as multiple revenue streams converge—from on-chain activity fees to s...
Institutional investors are pouring money back into XRP ETFs, driving inflows to a five-month high. Analysts say this...
Oxbridge Re kicks off 2026 with a Q1 that mixes solid underwriting with measured investment moves. This deep dive exp...